<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="research-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">WASJ</journal-id>
<journal-title-group>
<journal-title>World Academy of Sciences Journal</journal-title>
</journal-title-group>
<issn pub-type="ppub">2632-2900</issn>
<issn pub-type="epub">2632-2919</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">WASJ-7-5-00369</article-id>
<article-id pub-id-type="doi">10.3892/wasj.2025.369</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glutathione-S-transferase pi-1 polymorphisms as predictors of the severity and onset of the development of cumulative oxaliplatin-induced neurotoxicity in patients with colorectal cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jawad</surname><given-names>Rehab A.M.</given-names></name>
<xref rid="af1-WASJ-7-5-00369" ref-type="aff">1</xref>
<xref rid="af2-WASJ-7-5-00369" ref-type="aff">2</xref>
<xref rid="c1-WASJ-7-5-00369" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Mshimesh</surname><given-names>Bahir A.</given-names></name>
<xref rid="af1-WASJ-7-5-00369" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Al-Mayah</surname><given-names>Qasim S.</given-names></name>
<xref rid="af3-WASJ-7-5-00369" ref-type="aff">3</xref>
</contrib>
</contrib-group>
<aff id="af1-WASJ-7-5-00369"><label>1</label>Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, 98HF+2R, Baghdad, Iraq</aff>
<aff id="af2-WASJ-7-5-00369"><label>2</label>Kimadia, Ministry of Health, 89XJ+2GR, Baghdad, Iraq</aff>
<aff id="af3-WASJ-7-5-00369"><label>3</label>Department of Medical Research Unit, College of Medicine, AL-Nahrain University, 98HF+2R, Baghdad, Iraq</aff>
<author-notes>
<corresp id="c1-WASJ-7-5-00369"><italic>Correspondence to:</italic> Dr Rehab A.M. Jawad, Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, 60 Alyarmouk Road, 98HF+2R, Baghdad, Iraq <email>rehab_abd_almuttalib@uomustansiriyah.edu.iq</email></corresp>
</author-notes>
<pub-date pub-type="collection"><season>Sep-Oct</season><year>2025</year></pub-date>
<pub-date pub-type="epub"><day>25</day><month>06</month><year>2025</year></pub-date>
<volume>7</volume>
<issue>5</issue>
<elocation-id>81</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>02</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>06</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2025 Jawad et al.</copyright-statement>
<copyright-year>2025</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license>
</permissions>
<abstract>
<p>Colorectal cancer (CRC) is a major global health burden, and oxaliplatin is a cornerstone of its treatment. However, oxaliplatin-induced neurotoxicity, particularly chronic cumulative neurotoxicity (CN), poses a significant clinical challenge, often severely compromising the quality of life of patients. Genetic polymorphisms in glutathione S-transferase pi-1 (<italic>GSTP1</italic>) may influence individual susceptibility to oxaliplatin-induced neurotoxicity. The present study investigated the association between <italic>GSTP1</italic> polymorphisms (rs1695 and rs1138272) and CN in patients with CRC receiving oxaliplatin-based chemotherapy. For this purpose, a prospective observational cohort study was conducted across two oncology centers, enrolling 120 patients with CRC. <italic>GSTP1</italic> polymorphisms were genotyped using polymerase chain reaction and Sanger sequencing. CN severity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events. Logistic regression analysis was used to assess the association between GSTP1 genotypes and neurotoxicity onset and severity. Significant associations were observed between <italic>GSTP1</italic> polymorphisms and the risk of developing CN. The rs1695 GG genotype conferred a 7.7-fold increased risk of developing CN at oxaliplatin doses &#x003C;1,000 mg/m<sup>2</sup> (P=0.012) and a 5.5-fold risk at doses &#x003E;1,000 mg/m<sup>2</sup> (P&#x003C;0.001). The rs1138272 CT genotype was found to be associated with an elevated risk of developing CN &#x005B;odds ratio (OR), 4.05; P=0.004&#x005D;, implicating the T allele in susceptibility. The GG genotype was strongly associated with progressive CN severity, exhibiting a 5-fold risk for grade 2 (P=0.031) and a 6.2-fold risk for grade 3 CN (P=0.029). Similarly, the CT genotype was associated with grade 3 CN. (OR, 3.43; P=0.043). To the best of our knowledge, the present study is the first to demonstrate a link between the rs1695 and rs1138272 polymorphisms and the onset and severity of CN. On the whole, the present study demonstrates that <italic>GSTP1</italic> polymorphisms significantly affect the oxaliplatin-induced risk of developing CN in patients with CRC. These findings advocate genetic screening as part of personalized treatment strategies and underscore the need for further mechanistic and validation studies.</p>
</abstract>
<kwd-group>
<kwd>cumulative neurotoxicity</kwd>
<kwd>dose-limiting toxicity</kwd>
<kwd>pharmacogenetics</kwd>
<kwd>glutathione-S-transferase pi-1 polymorphism</kwd>
<kwd>oxaliplatin</kwd>
<kwd>colorectal cancer</kwd>
</kwd-group>
<funding-group>
<funding-statement><bold>Funding:</bold> The genotyping component of the present study was financially supported by the Holy Shrine of Imam Husayn.</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Colorectal cancer (CRC) imposes a substantial global health burden, with region-specific risk factors exacerbating its impact. In Iraq, <italic>Helicobacter pylori</italic> infection, particularly cytotoxic CagA-positive strains, has been linked to the increased incidence of CRC (<xref rid="b1-WASJ-7-5-00369" ref-type="bibr">1</xref>). The financial burden of cancer care further compounds healthcare disparities, limiting equitable treatment access (<xref rid="b2-WASJ-7-5-00369" ref-type="bibr">2</xref>,<xref rid="b3-WASJ-7-5-00369" ref-type="bibr">3</xref>).</p>
<p>Oxaliplatin, a platinum-based chemotherapeutic agent, is integral to CRC treatment across disease stages (<xref rid="b4-WASJ-7-5-00369" ref-type="bibr">4</xref>,<xref rid="b5-WASJ-7-5-00369" ref-type="bibr">5</xref>). Its mechanism involves DNA crosslinking at the N7 position of guanine, inducing structural distortion, replication blockade and apoptosis (<xref rid="b6-WASJ-7-5-00369" ref-type="bibr">6</xref>). However, oxaliplatin also elicits dose-limiting neurotoxicity, including acute cold-induced symptoms and chronic cumulative neurotoxicity (CN), which often necessitates dose modifications and markedly impairs the quality of life of patients (<xref rid="b7-WASJ-7-5-00369" ref-type="bibr">7</xref>).</p>
<p>CN typically emerges following 8-10 treatment cycles (incidence rate, 40-93&#x0025;) (<xref rid="b8-WASJ-7-5-00369" ref-type="bibr">8</xref>), with symptoms persisting between cycles and worsening at cumulative doses exceeding 700-800 mg/m<sup>2</sup> (<xref rid="b9-WASJ-7-5-00369" ref-type="bibr">9</xref>). Sensory nerve conduction deficits manifest early (e.g., at 410 mg/m<sup>2</sup>) and progress with dose escalation (<xref rid="b10-WASJ-7-5-00369" ref-type="bibr">10</xref>).</p>
<p>The glutathione S-transferase pi-1 (<italic>GSTP1</italic>) gene (chromosome 11q13) encodes a detoxification enzyme critical for metabolizing carcinogens and chemotherapeutics (<xref rid="b11-WASJ-7-5-00369" ref-type="bibr">11</xref>). Comprising &#x007E;4&#x0025; of hepatic soluble proteins, GSTP1 functions as a dimer with G- and H-sites that bind glutathione to facilitate xenobiotic detoxification. Polymorphisms in <italic>GSTP1</italic> may alter substrate affinity, influencing drug efficacy and toxicity (<xref rid="b12-WASJ-7-5-00369" ref-type="bibr">12</xref>).</p>
<p>In oxaliplatin-induced neurotoxicity, <italic>GSTP1</italic> plays a dual role: i) By detoxifying oxaliplatin metabolites; and ii) modulating neurotoxic pathways (<xref rid="b13-WASJ-7-5-00369" ref-type="bibr">13</xref>,<xref rid="b14-WASJ-7-5-00369" ref-type="bibr">14</xref>). It regulates the Nrf2-Keap1 oxidative stress response (<xref rid="b11-WASJ-7-5-00369" ref-type="bibr">11</xref>,<xref rid="b15-WASJ-7-5-00369" ref-type="bibr">15</xref>) and interacts with DNA repair mechanisms; impaired function may exacerbate neuronal DNA damage and apoptosis (<xref rid="b12-WASJ-7-5-00369" ref-type="bibr">12</xref>,<xref rid="b16-WASJ-7-5-00369" ref-type="bibr">16</xref>). Additionally, <italic>GSTP1</italic> modulates transient receptor potential cation channel subfamily A member 1 expression, an ion channel implicated in neuropathic pain (<xref rid="b17-WASJ-7-5-00369" ref-type="bibr">17</xref>).</p>
<p>The present study examined <italic>GSTP1</italic> polymorphisms (rs1695 and rs1138272) as predictive biomarkers for CN in Iraqi patients with CRC, aiming to optimize treatment cycles and guide therapeutic alternatives.</p>
</sec>
<sec sec-type="Patients|methods">
<title>Patients and methods</title>
<sec>
<title/>
<sec>
<title>Study design</title>
<p>A prospective observational cohort study was conducted between January, 2024 and January, 2025 at two Iraqi oncology centers (Oncology Teaching Hospital, Medical City, Baghdad and Warith International Cancer Institute, Karbala) in an aim to evaluate the association between <italic>GSTP1</italic> polymorphisms (rs1695 and rs1138272) and oxaliplatin-induced CN in patients with advanced-stage CRC. Of the 150 initially screened patients, 120 eligible Iraqi adults (61 males and 59 females) with histologically confirmed colorectal adenocarcinoma were enrolled in the present study.</p>
</sec>
<sec>
<title>Inclusion and exclusion criteria</title>
<p>The inclusion criteria were patients with histologically confirmed CRC and those treated with planned oxaliplatin-based chemotherapy at a cumulative dose &#x2265;500 mg/m<sup>2</sup>. The exclusion criteria were patients with pre-existing neuropathy or those previously treated with platinum-based chemotherapy.</p>
</sec>
<sec>
<title>Clinical data collection</title>
<p>The present study adhered to the NCCN Clinical Practice Guidelines in Oncology-Colon Cancer v.2024(<xref rid="b18-WASJ-7-5-00369" ref-type="bibr">18</xref>) to maintain consistency in patient care and outcome assessment. Clinical assessments were conducted systematically prior to each chemotherapy cycle. Symptoms of CN were assessed at baseline and subsequently monitored through follow-up evaluations conducted 2 weeks post-administration of each chemotherapy cycle. The evaluations comprised physical examinations and complete blood count tests. The cumulative neurotoxicity resulting from oxaliplatin was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) (<xref rid="b19-WASJ-7-5-00369" ref-type="bibr">19</xref>). Although objective tools for assessing chemotherapy-induced neurotoxicity were not employed, thorough clinical evaluations provided consistent and reliable monitoring of CN-related symptoms.</p>
</sec>
<sec>
<title>Collection of genetic data</title>
<p>Alongside clinical assessments, blood samples were obtained from all participants for the analysis of <italic>GSTP1</italic> gene polymorphisms. Patients were classified into two groups according to their cumulative oxaliplatin dosage: Those with a total dose &#x003C;1,000 mg/m<sup>2</sup> and those with a total dose &#x003E;1,000 mg/m<sup>2</sup>. The categorization aimed to assess the impact of genetic variations on the initiation timing of CN. The present study aimed to integrate clinical data and genetic analysis to provide evidence on the potential role of <italic>GSTP1</italic> polymorphisms in predicting susceptibility to CN.</p>
</sec>
<sec>
<title>Ethical considerations and approvals</title>
<p>The research adhered to Good Clinical Practice (GCP) principles; the present study adhered to ethical standards established by the Research Ethics Committee of Mustansiriyah University of Pharmacy (permission no. 37) and was granted authorization from the Ministry of Health (no. 7026) and approvals from the Ministry of Health (no. 7026) and Warith International Cancer Institute (no. 892). The permission form emphasized that participation was entirely voluntary, and individuals could withdraw at any time without incurring any consequences. Anonymity and confidentiality were preserved by using coded identifiers instead of names or medical record numbers. The research upheld rigorous ethical standards in accordance with international ethical norms, including the Declaration of Helsinki. A statement of consent for publication was obtained from the patient according to the principles of the Declaration of Helsinki.</p>
</sec>
<sec>
<title>DNA extraction and polymerase chain reaction (PCR)</title>
<p>The genomic DNA was purified from peripheral white blood cells (isolated form collected blood samples from each patient) and extracted according to the protocol of the manufacturer using the ReliaPrep<sup>&#x2122;</sup> Blood gDNA Miniprep kit (cat. no. A5081, Promega Corporation) and stored at -20&#x02DA;C until the use in PCR. Of note, two pairs of primers were used to amplify gene fragments corresponding to the target polymorphisms. The sequences of these primers were as follows: rs-1695 forward, 5&#x0027;-ACGCACATCCTCTTCCCCTC-3&#x0027; and reverse, 5&#x0027;-TACTTGGCTGGTTGATGTCC-3&#x0027;; and rs-1138272 forward, 5&#x0027;-CAAGGATGGACAGGCAGAATGG-3&#x0027; and reverse, 5&#x0027;-ATGGCTCACACCTGTGTCCATC-3&#x0027;. The reference gene used was HLA-DRB1 gene for which the primer sequences were: DRB1 forward, 5&#x0027;-TGCCAAGTGGAGCACCCAA-3&#x0027; and reverse, 5&#x0027;-GCATCTTGCTCTGTGCAGAT-3&#x0027;.</p>
<p>All the PCR analyses were done according to the manufacturing protocol utilizing the GoTaq<sup>&#x00AE;</sup> Green Master Mix kit (cat. no. M7122, Promega Corporation) and using a reaction volume of 25 &#x00B5;l containing 3 &#x00B5;l DNA, Green Master Mix (12.5 &#x00B5;l), 1 &#x00B5;l of each primer (10 pmol), and 7.5 &#x00B5;l of nuclease-free water (<xref rid="b20-WASJ-7-5-00369" ref-type="bibr">20</xref>). PCR was conducted in a Veriti thermal cycler (cat. no. 4375305, Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR conditions included an initial denaturation at 95&#x02DA;C for 5 min, followed by 30 cycles of denaturation at 95&#x02DA;C for 30 sec, annealing at 60&#x02DA;C for 30 sec, and extension at 72&#x02DA;C for 30 sec. After cycling, a final extension at 72&#x02DA;C for 7 min was performed, and the reaction was held at 10&#x02DA;C for 10 min or as needed. The amplification products (5 &#x00B5;l) underwent electrophoresis on a 1.5&#x0025; agarose gel and using 100 bp DNA Ladder kit (cat. no. 15628019, Thermo Fisher Scientific, Inc.). The genotyping of exon 5 and 6 of the <italic>GSTP1</italic> polymorphism was conducted according to the instructions of the manufacturer using Sangar sequencing by Applied Biosystems<sup>&#x2122;</sup> SeqStudio<sup>&#x2122;</sup> Genetic Analyzer System with SmartStart utilizing Smart Start, System (cat. no. A35644; Applied Biosystems; Thermo Fisher Scientific, Inc.), SeqStudio<sup>&#x2122;</sup> Cartridge (cat. no. A33671), SeqStudio<sup>&#x2122;</sup> Cathode Buffer Container (cat. no. A33401), SeqStudio<sup>&#x2122;</sup> Integrated Capillary Protector (cat. no. A31923) and the Sanger Sequencing Kit (cat. no. A38073) (all from Applied Biosystems; Thermo Fisher Scientific, Inc.). The sequencing data were interpreted using Mutation Surveyor software (SoftGenetics, LLC). The corresponding chromatograms of rs1695 and rs1138272 in homozygous and heterozygous states are illustrated in <xref rid="f1-WASJ-7-5-00369" ref-type="fig">Figs. 1</xref>, <xref rid="f2-WASJ-7-5-00369" ref-type="fig">2</xref>, <xref rid="f3-WASJ-7-5-00369" ref-type="fig">3</xref> and <xref rid="f4-WASJ-7-5-00369" ref-type="fig">4</xref>.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>The distribution of continuous variables was assessed using the Shapiro-Wilk test for normality. Normally distributed data are expressed as the mean &#x00B1; standard deviation and analyzed using the Student&#x0027;s t-test, while non-normally distributed variables are summarized as the median (range) and compared using the Mann-Whitney U test. Categorical variables are reported as frequencies and percentages, with group differences were evaluated using the Chi-squared test of Fisher&#x0027;s exact test. To examine the association between <italic>GSTP1</italic> polymorphisms and CN, binary logistic regression was performed, adjusting for potential confounding factors where appropriate. Additional analyses assessed the association between genetic variants and both the threshold oxaliplatin dose for CN onset and the severity of neurotoxic manifestations. These associations were quantified using odds ratios (OR) with corresponding 95&#x0025; confidence intervals (CIs). Genotype frequencies were tested for deviation from Hardy-Weinberg equilibrium (HWE) using an online calculator (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scienceprimer.com/hardy-weinberg-equilibrium-calculator">https://scienceprimer.com/hardy-weinberg-equilibrium-calculator</ext-link>). All statistical tests were two-tailed, with P&#x003C;0.05 considered to indicate a statistically significant difference. Analyses were conducted using IBM SPSS Statistics for Windows (Version 25; IBM Corp.).</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Demographic and clinical data, and association with oxaliplatin-induced CN</title>
<p>The present study analyzed multiple variables among the 120 patients enrolled in the present study, including genetic polymorphisms, tumor characteristics and treatment parameters. Of these participants, 53 (44.2&#x0025;) developed oxaliplatin-induced CN, while 67 (55.8&#x0025;) did not exhibit this adverse effect.</p>
<p>The comprehensive analysis of demographic and clinical characteristics revealed no significant associations between baseline factors and the development of CN. As detailed in <xref rid="tI-WASJ-7-5-00369" ref-type="table">Tables I</xref> and <xref rid="tII-WASJ-7-5-00369" ref-type="table">II</xref>, no statistically significant differences were observed between the demographics of the patients with and without CN.</p>
</sec>
<sec>
<title>Association of treatment data with oxaliplatin-induced CN</title>
<p>Although the analysis revealed a non-significant association between cumulative oxaliplatin exposure and neurotoxicity development. As demonstrated in <xref rid="tIII-WASJ-7-5-00369" ref-type="table">Table III</xref>, patients receiving higher cumulative doses (&#x003E;1,000 mg/m<sup>2</sup>) exhibited a substantially greater incidence of CN compared to those receiving lower doses. Although not statistically significant, this dose-dependent association persisted following the adjustment for potential confounding variables (concomitant medications such as statins and renin-angiotensin system inhibitors), supporting cumulative dose as a key determinant of the risk of developing neurotoxicity.</p>
</sec>
<sec>
<title>Genetic predisposition to oxaliplatin induces CN: HWE validation and high-risk genotypes (rs1695 and rs1138272)</title>
<p>Genotype distributions for rs1695 and rs1138272 were tested for HWE using a Chi-squared test calculated via an online calculator (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://scienceprimer.com/hardy-weinberg-equilibrium-calculator">https://scienceprimer.com/hardy-weinberg-equilibrium-calculator</ext-link>). Both polymorphisms were in equilibrium (rs1695: &#x03C7;<sup>2</sup>=1.77, df=1, P=0.412; rs1138272: &#x03C7;<sup>2</sup>=0.002, df=1, P=0.999), indicating no significant deviation from HWE. Since both P-values were &#x003E;0.05, the genotype distributions do not significantly deviate from HWE, as shown in <xref rid="tIV-WASJ-7-5-00369" ref-type="table">Table IV</xref>.</p>
<p>The sequencing PCR products of rs1695 revealed three genotypes (AA, AG and GG). The sequencing of PCR products of rs1138272 also revealed three genotypes (CC, CT and TT). The results of the association between genotypes of both polymorphisms linked to CN in patients receiving oxaliplatin-based chemotherapy are presented in <xref rid="tV-WASJ-7-5-00369" ref-type="table">Tables V</xref> and <xref rid="tVI-WASJ-7-5-00369" ref-type="table">VI</xref>. The GG and CT genotypes posed the highest risk (OR, 4.0; 95&#x0025; CI, 1.08-14.74) and (OR, 5.27; 95&#x0025; CI, 2.0-13.79) for rs1695 and rs1138272, respectively. These genotypes were found to significantly increase the risk of developing CN, suggesting a strong genetic predisposition.</p>
</sec>
<sec>
<title>Dose-dependent genetic associations between rs1695/rs1138272 and oxaliplatin-induced CN</title>
<p>The association between the polymorphisms and two different ranges of doses (&#x003C;1,000 mg/m<sup>2</sup> and &#x003E;1,000 mg/m<sup>2</sup>) was then examined (<xref rid="tVII-WASJ-7-5-00369" ref-type="table">Tables VII</xref>, <xref rid="tVIII-WASJ-7-5-00369" ref-type="table">VIII</xref>, <xref rid="tIX-WASJ-7-5-00369" ref-type="table">IX</xref>, and <xref rid="tX-WASJ-7-5-00369" ref-type="table">X</xref>). The key findings revealed that the rs1695 polymorphism was strongly associated with CN at oxaliplatin doses (&#x003C;1,000 mg/m<sup>2</sup>; the GG genotype increased the risk of developing CN by &#x007E;7.7-fold compared to the AA genotype (OR, 7.7; P=0.012) (<xref rid="tVII-WASJ-7-5-00369" ref-type="table">Table VII</xref>). At oxaliplatin doses &#x003E;1,000 mg/m<sup>2</sup>, the risk remained elevated, with the AG genotype increasing the odds by 5.5-fold compared to the AA genotype (OR, 5.5; P&#x003C;0.001), as shown in <xref rid="tVIII-WASJ-7-5-00369" ref-type="table">Table VIII</xref>.</p>
<p>As regards rs1138272, at doses (&#x003C;1,000 mg/m<sup>2</sup>, the CT genotype was significantly associated with CN (P=0.004), with a recessive model OR of 4.05. This indicates that individuals carrying at least one T allele (CT or TT) are at a &#x003E;4-fold increased risk of developing CN compared to those without this allele, as shown in <xref rid="tIX-WASJ-7-5-00369" ref-type="table">Table IX</xref>. The rs 1138272 polymorphism did not exhibit a significant correlation with CN at doses &#x003E;1,000 mg/m<sup>2</sup> oxaliplatin, as shown in <xref rid="tX-WASJ-7-5-00369" ref-type="table">Table X</xref>.</p>
</sec>
<sec>
<title>Dose-independent genetic associations: rs1695 GG/AG and rs1138272 CT genotypes are associated with grade-progressive risk of developing oxaliplatin-induced CN</title>
<p>The present study then examined the association between different genotypes and alleles of the rs1695 polymorphism with varying grades of cumulative neurotoxicity. The findings indicated that both the G allele and the GG genotype of the GSTP1 rs1695 polymorphism were significantly associated with increased severity of cumulative neurotoxicity, particularly at grades 2 and 3 (<xref rid="tXI-WASJ-7-5-00369" ref-type="table">Table XI</xref>) between the GG genotype and the increased the severity of CN.</p>
<p>Individuals carrying the AG genotype had a significantly increased risk of developing grade 1 CN compared to the AA genotype (OR, 3.62; 95&#x0025; CI, 1.36-9.65; P=0.010). The GG genotype did not exhibit a statistically significant association with grade 1 CN (OR, 1.45; P=0.666). The G allele was significantly associated with grade 1 CN (OR, 2.27; P=0.015), suggesting that carriers of the G allele may be predisposed to early-stage CN.</p>
<p>A strong association was observed between the GG genotype and grade 2 CN (OR, 5.0; 95&#x0025; CI, 1.56-21.63; P=0.031), indicating that homozygous carriers of the G allele have a 5-fold increased risk of developing grade 2 CN compared to the AA genotype. The AG genotype does not exhibit a significant association with grade 2 CN (P=0.638). The G allele again exhibited a significant association with grade 2 CN (OR, 2.65; P=0.042), reinforcing its potential role in the increased susceptibility to CN.</p>
<p>Both the AG and GG genotypes exhibited significant associations with grade 3 CN. The AG genotype was associated with an almost 5-fold increased risk of grade 3 CN (OR, 4.94; P=0.024). The GG genotype exhibited the highest association (OR, 6.2; P=0.029), suggesting a dose-dependent association between the number of G alleles and the severity of CN. The G allele remained significantly associated with grade 3 CN (OR, 3.65; P=0.001) (<xref rid="tXI-WASJ-7-5-00369" ref-type="table">Table XI</xref>).</p>
<p>Subsequently, the present study examined the impact of the rs1138272 polymorphism on oxaliplatin-induced CN (<xref rid="tXII-WASJ-7-5-00369" ref-type="table">Table XII</xref>). The data indicated that the CT genotype was associated with an increased risk of developing CN, particularly at higher grades. The CT and TT genotypes do not exhibit a significant association with grade 1 CN (P&#x003E;0.05 for both). The T allele did not demonstrate a statistically significant association with grade 1 CN (OR, 1.47; P=0.389), suggesting that rs1138272 may not strongly contribute to early-stage CN.</p>
<p>The CT genotype exhibited a trend towards an increased risk of grade 2 CN (OR, 2.60; P=0.100), although the association was not statistically significant. The TT genotype is absent in patients with grade 2, preventing any conclusive interpretation. The CT genotype was significantly associated with grade 3 CN (OR, 3.43; 95&#x0025; CI, 1.04-11.28; P=0.043). The T allele exhibited a potential association with grade 3 CN (OR, 3.29; P=0.052), although this was not statistically significant (<xref rid="tXII-WASJ-7-5-00369" ref-type="table">Table XII</xref>), indicating a high variability and a need for further validation in larger cohort studies.</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>The present study provides compelling evidence of the role of genetic polymorphisms in modifying susceptibility to oxaliplatin-induced CN, while simultaneously confirming the established dose-dependent nature of this adverse effect. These findings highlight the clinical utility of genetic screening in risk stratification, facilitating the personalization of chemotherapy regimens to effectively minimize oxaliplatin-related CN.</p>
<p>Notably, both polymorphisms-maintained the HWE, strengthening confidence in the genetic findings obtained herein and suggesting that these variants represent true population characteristics rather than genotyping artifacts or selection biases. The findings of the present study suggest that individuals with the G allele (homozygous GG) and T allele contribute to an increased risk of developing oxaliplatin-related CN, particularly at doses &#x003C;1,000 mg/m<sup>2</sup>. Of note, the higher chance of requiring a dose reduction for both the GG and CT genotypes may be due to the fact that they had their treatment adjusted or had longer breaks between treatment cycles to manage the risk of oxaliplatin-related CN. That could cause an apparent fall in OR due to increased cumulative dosing. In addition, it could mean both genotypes are associated with early-onset CN. These results are consistent with the theory that both polymorphisms rs1695 and rs1138272 in the <italic>GSTP1</italic> gene involve amino acid substitutions that appear to be within the GSTP1 active site and lead to the alteration of substrate affinity. The substitution of adenine by guanine in exon 5 at nucleotide 313 results in valine &#x005B;Val&#x005D; replacing isoleucine &#x005B;Ile&#x005D; in location 105 of the amino acid sequence (<xref rid="b21-WASJ-7-5-00369" ref-type="bibr">21</xref>,<xref rid="b22-WASJ-7-5-00369" ref-type="bibr">22</xref>). Replacing cysteine with thiamin in exon 6 at nucleotide 341 causes valine &#x005B;Val&#x005D; to take the place of alanine &#x005B;Ala&#x005D; at position 114 in the amino acid sequence. This substitution may disrupt the ability of the enzyme to interact critically with glutathione, potentially reducing its detoxification capacity. The structural integrity and flexibility provided by cysteine residues are essential for maintaining the active site&#x0027;s conformation, which is vital for effective substrate binding (<xref rid="b23-WASJ-7-5-00369" ref-type="bibr">23</xref>).</p>
<p>In a previous study involving Caucasian patients (<xref rid="b24-WASJ-7-5-00369" ref-type="bibr">24</xref>), the prevalence of CN was found to be 52.1&#x0025;, with 36.8&#x0025; experiencing grade II neurotoxicity. These numbers differ from those observed in the present study (44.2 and 12.5&#x0025;, respectively). This disparity may be attributed to differences in genetic backgrounds and allele frequencies, as previously discussed (<xref rid="b25-WASJ-7-5-00369" ref-type="bibr">25</xref>).</p>
<p>In a previous study involving Caucasian patients, the prevalence of CN was found to be 52.1&#x0025;, with 36.8&#x0025; experiencing grade II neurotoxicity (<xref rid="b24-WASJ-7-5-00369" ref-type="bibr">24</xref>). The findings demonstrate that 44&#x0025; developed chronic neurotoxicity, with 12.5&#x0025; experiencing grade II CN. This disparity may be due to the difference in genetic background and allele frequency (<xref rid="b25-WASJ-7-5-00369" ref-type="bibr">25</xref>).</p>
<p>The findings of the present study are consistent with those of previous research indicating that Japanese individuals with at least one <italic>GSTP1</italic> 105Val allele are more likely to develop early-onset grade 2/3 neuropathy from oxaliplatin (<xref rid="b26-WASJ-7-5-00369" ref-type="bibr">26</xref>,<xref rid="b27-WASJ-7-5-00369" ref-type="bibr">27</xref>). Additionally, another study involving 122 patients in Japan found that those with the AG allele experienced more severe neuropathy compared to those with the AA genotype (<xref rid="b12-WASJ-7-5-00369" ref-type="bibr">12</xref>). Furthermore, having the homozygous <italic>GSTP1</italic> variant (GG) was shown to be associated with a higher likelihood of experiencing grade &#x2265;3 peripheral neuropathy when compared to the wild-type (AA) (<xref rid="b12-WASJ-7-5-00369" ref-type="bibr">12</xref>).</p>
<p>The results presented herein are in accordance with the hypothesis that the <italic>GSTP1</italic> 105Ile variant can lead to increased oxidative stress and neuronal damage (<xref rid="b1-WASJ-7-5-00369" ref-type="bibr">1</xref>), exacerbating oxaliplatin-induced CN (<xref rid="b28-WASJ-7-5-00369" ref-type="bibr">28</xref>). Research have shown that patients with the Ile105 variant may experience more severe neuropathy, highlighting the clinical relevance of this polymorphism in oxaliplatin treatment (<xref rid="b25-WASJ-7-5-00369" ref-type="bibr">25</xref>). Another retrospective study demonstrated that European patients with the Val/Val or Ile/Val genotypes were more likely to have a decreased risk of severe oxaliplatin-related CN (<xref rid="b28-WASJ-7-5-00369" ref-type="bibr">28</xref>). A previous meta-analysis of heterogeneity for <italic>GSTP1</italic> Ile105Val and oxaliplatin-induced neuropathy demonstrated no significant association between <italic>GSTP1</italic> polymorphism and neurotoxicity (<xref rid="b13-WASJ-7-5-00369" ref-type="bibr">13</xref>). This indicates that the frequencies of the alleles in Asian populations differ significantly from those in Caucasian populations (<xref rid="b25-WASJ-7-5-00369" ref-type="bibr">25</xref>). Based on previous research, the conjugation of oxaliplatin with glutathione is not the only pathway for biotransformation and does not play a substantial role in its effectiveness and side-effects (<xref rid="b29-WASJ-7-5-00369" ref-type="bibr">29</xref>). Protein-protein interaction between JNK with wild-type <italic>GSTP1</italic> exhibit a higher affinity than mutant <italic>GSTP1</italic> (<xref rid="b30-WASJ-7-5-00369" ref-type="bibr">30</xref>). The JNK protein interacts with the mitochondrial protein SAB, and the interaction forms a JNK-SAB-ROS activation loop that impairs electron transport and promotes the release of reactive oxygen species, contributing to apoptosis (<xref rid="b31-WASJ-7-5-00369" ref-type="bibr">31</xref>).</p>
<p>Ultimately, the modulation of apoptosis depends on the redox status of cells (<xref rid="b32-WASJ-7-5-00369" ref-type="bibr">32</xref>). Phosphorylation can enhance GSTP1 activity and can potentially affect signaling pathways, including the signal transducer and activator of transcription pathway involved in the inflammatory response (<xref rid="b33-WASJ-7-5-00369" ref-type="bibr">33</xref>). Recent research has illustrated the involvement of immune reactions and inflammation in the body, each of which is diagnosed to contribute to the development of neuropathy (<xref rid="b8-WASJ-7-5-00369" ref-type="bibr">8</xref>). It was hypothesized that mutant <italic>GSTP1</italic> is essential for sustaining JNK activation and that mutant <italic>GSTP1</italic> is activated by phosphorylation with various kinases more than the wild-type on the above bases. However, the mechanisms of oxaliplatin-induced CN rely on the unique structure and function of the neurons, and the complex communication between neurons, the immune system and cancer cells must be considered. The overall impact of this polymorphism on oxaliplatin-induced CN remains complex and may involve other genetic and environmental factors. The results should be interpreted cautiously as some studies used different designs and genotyping methods. To the best of our knowledge, the present study appears to be the first to report that genotypes of the rs1695 and rs1138272 polymorphisms are associated with the severity and onset of cumulative neurotoxicity in West Asia. According to these findings, it can be hypothesized that the variation between West and East Asia is closer than that in Caucasians.</p>
<p>The findings of the present study carry important clinical implications. First, the findings suggest that pharmacogenetic testing may be most valuable for patients anticipated to receive moderate cumulative doses, where genotype could meaningfully influence risk-benefit calculations. Second, these findings indicate that while high-dose regimens universally increase the risk of developing CN, genetic factors still contribute meaningfully even in these scenarios. Several practical applications emerge from these findings: i) Preemptive risk assessment: Incorporating rs1695 and rs1138272 genotyping into pre-treatment workups could identify high-risk patients prior to the development of CN. This may be particularly valuable when considering extended adjuvant regimens where cumulative doses approach risk thresholds. ii) Personalized dosing strategies: For high-genetic-risk patients, clinicians might consider the following: Lower cumulative dose ceilings (e.g., &#x003C;850 mg/m<sup>2</sup> for GG/CT carriers), enhanced monitoring protocols and alternative dosing schedules (e.g., stop-and-go approaches). iii) Regimen selection: In clinical scenarios with equivalent therapeutic options (e.g., FOLFOX vs. XELOX in colorectal cancer), genetic risk profiles can guide regimen selection. In addition, population specificity should be considered: The generalizability of the findings to diverse ethnic populations requires verification, as allele frequencies and linkage patterns may vary across groups.</p>
<p>The present study has certain limitations, which should be mentioned. First, a limited cohort of patients were assessed. The data presented herein should thus be regarded as preliminary. Further studies utilizing the same oxaliplatin-based chemotherapy are necessary to validate the potential of the <italic>GSTP1</italic> genotype as a key indicator of CN associated with this treatment. Secondly, the time line of the present study was limited, which did not allow for follow-up on chronic CN to assess whether genetic risk profiles predict long-term neuropathy persistence or recovery patterns.</p>
<p>In conclusion, in the present study, the analysis of polymorphisms rs1695 and rs1138272 revealed meaningful links between certain genotypes and the severity and onset of CN. Genetic analysis revealed significant associations between rs1695 and rs1138272 polymorphisms and oxaliplatin-related CN. To the best of our knowledge, the present study is the first study to demonstrate a link between rs1695 and rs1138272 polymorphisms and the onset and severity of CN in West Asian populations. These findings support the integration of genetic screening into personalized treatment strategies and highlight the need for further research to validate these associations and elucidate the underlying mechanisms. Further research is warranted to fully elucidate the association between <italic>GSTP1</italic> polymorphisms, apoptosis pathways in the neurons and neurotoxicity in the context of chemotherapy.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>The authors extend their sincere appreciation to Dr Fawaz S. Al-Alloosh, Head of the Medical Oncology Department at Warith International Cancer Institute, Karbala, and Dr Mohammed Ghanim Mehdi, Head of the Laboratory at Warith International Cancer Institute, Karbala, for their invaluable guidance and support throughout this research. Additionally, the authors would like to extent their appreciation to Mustansiriyah University, Baghdad, Iraq (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uomustansiriyah.edu.iq">www.uomustansiriyah.edu.iq</ext-link>), for providing academic and administrative assistance.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The data generated in the present study may be requested from the corresponding author.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>RAMJ made substantial contributions to the conception and design of the study/ RAMJ also collected blood samples from the patients and performed the laboratory analyses, and also participated in the acquisition, analysis and interpretation of the data, generated the datasets, and drafted and revised the manuscript. BAM played a role in the conceptualization, designing methodology of study, data curation and writing the original draft. QSAM contributed to performing the data analysis and revising the manuscript. All authors (RAMJ, BAM and QSAM) confirm the authenticity of all the raw data. All authors have read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>The present study complied with the principles of Good Clinical Practice (GCP), ethical standards set by the Research Ethics Committee of Mustansiriyah University of Pharmacy (ref. no. 105). Approval was obtained from the Ministry of Health (no. 7026) and Warith International Cancer Institute (no.892). The consent form emphasized that participation was entirely voluntary, and the participants could withdraw at any time without facing any repercussions. Anonymity and confidentiality were safeguarded by assigning coded identifiers rather than names or medical record numbers. In adherence to international ethical guidelines, including the Declaration of Helsinki, the study maintained strict ethical standards. A statement of consent for publication was obtained from the patient according to the principles of the Declaration of Helsinki.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-WASJ-7-5-00369"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakir</surname><given-names>WA</given-names></name><name><surname>Ismail</surname><given-names>NH</given-names></name><name><surname>Latif</surname><given-names>AH</given-names></name><name><surname>Abd</surname><given-names>DW</given-names></name><name><surname>Saied</surname><given-names>ZZ</given-names></name></person-group><article-title>Cytotoxicity-associated gene (CagA) producing <italic>Helicobacter pylori</italic> increased risk of developing colorectal carcinoma in Iraqi patients</article-title><source>Al Mustansiriyah J Pharm Sci</source><volume>14</volume><fpage>143</fpage><lpage>149</lpage><year>2014</year></element-citation></ref>
<ref id="b2-WASJ-7-5-00369"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>Temporal trends in the disease burden of colorectal cancer with its risk factors at the global and national level from 1990 to. 2019, and projections until 2044</article-title><source>Clin Epidemiol</source><volume>15</volume><fpage>55</fpage><lpage>71</lpage><year>2023</year><pub-id pub-id-type="pmid">36659904</pub-id><pub-id pub-id-type="doi">10.2147/CLEP.S388323</pub-id></element-citation></ref>
<ref id="b3-WASJ-7-5-00369"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobritz</surname><given-names>M</given-names></name><name><surname>Nofi</surname><given-names>CP</given-names></name><name><surname>Egunsola</surname><given-names>A</given-names></name><name><surname>Zimmern</surname><given-names>AS</given-names></name></person-group><article-title>Financial toxicity in early-onset colorectal cancer: A national health interview survey study</article-title><source>Surgery</source><volume>175</volume><fpage>1278</fpage><lpage>1284</lpage><year>2024</year><pub-id pub-id-type="pmid">38378347</pub-id><pub-id pub-id-type="doi">10.1016/j.surg.2024.01.005</pub-id></element-citation></ref>
<ref id="b4-WASJ-7-5-00369"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Saigh</surname><given-names>THT</given-names></name><name><surname>Abdulmawjood</surname><given-names>SA</given-names></name><name><surname>Ahmed</surname><given-names>FA</given-names></name></person-group><article-title>Prognostic factor of serum carcinoembryonic antigen in colorectal cancer patients: A follow up study</article-title><source>Al Mustansiriyah J Pharm Sci</source><volume>21</volume><fpage>1</fpage><lpage>6</lpage><year>2022</year></element-citation></ref>
<ref id="b5-WASJ-7-5-00369"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jawad</surname><given-names>RAM</given-names></name><name><surname>Mshimesh</surname><given-names>BAR</given-names></name><name><surname>Al-Mayah</surname><given-names>QS</given-names></name><name><surname>Al-Alloosh</surname><given-names>F</given-names></name></person-group><article-title>A case study on complete pathological response in advanced rectal cancer patient with oxaliplatin-based chemotherapy without cumulative neurotoxicity</article-title><source>J Gastrointest Cancer</source><volume>56</volume><issue>99</issue><year>2025</year><pub-id pub-id-type="pmid">40240738</pub-id><pub-id pub-id-type="doi">10.1007/s12029-025-01227-7</pub-id></element-citation></ref>
<ref id="b6-WASJ-7-5-00369"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calls</surname><given-names>A</given-names></name><name><surname>Torres-Espin</surname><given-names>A</given-names></name><name><surname>Tormo</surname><given-names>M</given-names></name><name><surname>Mart&#x00ED;nez-Escard&#x00F3;</surname><given-names>L</given-names></name><name><surname>Bonet</surname><given-names>N</given-names></name><name><surname>Casals</surname><given-names>F</given-names></name><name><surname>Navarro</surname><given-names>X</given-names></name><name><surname>Yuste</surname><given-names>VJ</given-names></name><name><surname>Udina</surname><given-names>E</given-names></name><name><surname>Bruna</surname><given-names>J</given-names></name></person-group><article-title>A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice</article-title><source>Ann Clin Transl Neurol</source><volume>9</volume><fpage>1985</fpage><lpage>1998</lpage><year>2022</year><pub-id pub-id-type="pmid">36369764</pub-id><pub-id pub-id-type="doi">10.1002/acn3.51691</pub-id></element-citation></ref>
<ref id="b7-WASJ-7-5-00369"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaletti</surname><given-names>G</given-names></name><name><surname>Alberti</surname><given-names>P</given-names></name><name><surname>Marmiroli</surname><given-names>P</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics</article-title><source>Lancet Oncol</source><volume>12</volume><fpage>1151</fpage><lpage>1161</lpage><year>2011</year><pub-id pub-id-type="pmid">21719347</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70131-0</pub-id></element-citation></ref>
<ref id="b8-WASJ-7-5-00369"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name></person-group><article-title>Targeting strategies for oxaliplatin-induced peripheral neuropathy: Clinical syndrome, molecular basis, and drug development</article-title><source>J Exp Clin Cancer Res</source><volume>40</volume><issue>331</issue><year>2021</year><pub-id pub-id-type="pmid">34686205</pub-id><pub-id pub-id-type="doi">10.1186/s13046-021-02141-z</pub-id></element-citation></ref>
<ref id="b9-WASJ-7-5-00369"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stefansson</surname><given-names>M</given-names></name><name><surname>Nygren</surname><given-names>P</given-names></name></person-group><article-title>Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life</article-title><source>Acta Oncol</source><volume>55</volume><fpage>1227</fpage><lpage>1235</lpage><year>2016</year><pub-id pub-id-type="pmid">27550718</pub-id><pub-id pub-id-type="doi">10.1080/0284186X.2016.1197420</pub-id></element-citation></ref>
<ref id="b10-WASJ-7-5-00369"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grothey</surname><given-names>A</given-names></name></person-group><article-title>Clinical management of oxaliplatin-associated neurotoxicity</article-title><source>Clin Colorectal Cancer</source><volume>5 (Suppl 1)</volume><fpage>S38</fpage><lpage>S46</lpage><year>2005</year><pub-id pub-id-type="pmid">15871765</pub-id><pub-id pub-id-type="doi">10.3816/ccc.2005.s.006</pub-id></element-citation></ref>
<ref id="b11-WASJ-7-5-00369"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Lv</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><etal/></person-group><article-title>GSTP alleviates acute lung injury by S-glutathionylation of KEAP1 and subsequent activation of NRF2 pathway</article-title><source>Redox Biol</source><volume>71</volume><issue>103116</issue><year>2024</year><pub-id pub-id-type="pmid">38479222</pub-id><pub-id pub-id-type="doi">10.1016/j.redox.2024.103116</pub-id></element-citation></ref>
<ref id="b12-WASJ-7-5-00369"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katayanagi</surname><given-names>S</given-names></name><name><surname>Katsumata</surname><given-names>K</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Narahara</surname><given-names>K</given-names></name><name><surname>Shigoka</surname><given-names>M</given-names></name><name><surname>Matsudo</surname><given-names>T</given-names></name><name><surname>Enomoto</surname><given-names>M</given-names></name><name><surname>Suda</surname><given-names>T</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Hisada</surname><given-names>M</given-names></name><etal/></person-group><article-title>GSTP1 as a potential predictive factor for adverse events associated with platinum-based antitumor agent-induced peripheral neuropathy</article-title><source>Oncol Lett</source><volume>17</volume><fpage>2897</fpage><lpage>2904</lpage><year>2019</year><pub-id pub-id-type="pmid">30854066</pub-id><pub-id pub-id-type="doi">10.3892/ol.2019.9907</pub-id></element-citation></ref>
<ref id="b13-WASJ-7-5-00369"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name></person-group><article-title>Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: A systematic review and meta-analysis</article-title><source>Cancer Chemother Pharmacol</source><volume>72</volume><fpage>305</fpage><lpage>314</lpage><year>2013</year><pub-id pub-id-type="pmid">23695028</pub-id><pub-id pub-id-type="doi">10.1007/s00280-013-2194-x</pub-id></element-citation></ref>
<ref id="b14-WASJ-7-5-00369"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Ran</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: Mechanisms, pharmacokinetics and strategies</article-title><source>Front Pharmacol</source><volume>14</volume><issue>1231401</issue><year>2023</year><pub-id pub-id-type="pmid">37593174</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2023.1231401</pub-id></element-citation></ref>
<ref id="b15-WASJ-7-5-00369"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attarbashee</surname><given-names>RK</given-names></name><name><surname>Hamodat</surname><given-names>HF</given-names></name><name><surname>Mammdoh</surname><given-names>JK</given-names></name><name><surname>Ridha-Salman</surname><given-names>H</given-names></name></person-group><article-title>The possible effect of Bosentan on the methotrexate-induced salivary gland changes in male rats: Histological and Immunohistochemical study</article-title><source>Toxicol Res (Camb)</source><volume>14</volume><issue>tfaf007</issue><year>2025</year><pub-id pub-id-type="pmid">39830884</pub-id><pub-id pub-id-type="doi">10.1093/toxres/tfaf007</pub-id></element-citation></ref>
<ref id="b16-WASJ-7-5-00369"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>D</given-names></name><name><surname>Stabile</surname><given-names>AM</given-names></name><name><surname>Migni</surname><given-names>A</given-names></name><name><surname>Gurrado</surname><given-names>F</given-names></name><name><surname>Lioci</surname><given-names>G</given-names></name><name><surname>De Franco</surname><given-names>F</given-names></name><name><surname>Mandarano</surname><given-names>M</given-names></name><name><surname>Svegliati-Baroni</surname><given-names>G</given-names></name><name><surname>Di Cristina</surname><given-names>M</given-names></name><name><surname>Bellezza</surname><given-names>G</given-names></name><etal/></person-group><article-title>Subcellular distribution and Nrf2/Keap1-interacting properties of Glutathione S-transferase P in hepatocellular carcinoma</article-title><source>Arch Biochem Biophys</source><volume>757</volume><issue>110043</issue><year>2024</year><pub-id pub-id-type="pmid">38789086</pub-id><pub-id pub-id-type="doi">10.1016/j.abb.2024.110043</pub-id></element-citation></ref>
<ref id="b17-WASJ-7-5-00369"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Serna</surname><given-names>SN</given-names></name><name><surname>Almestica-Roberts</surname><given-names>M</given-names></name><name><surname>Burrell</surname><given-names>KL</given-names></name><name><surname>Nguyen</surname><given-names>ND</given-names></name><name><surname>Deering-Rice</surname><given-names>CE</given-names></name><name><surname>Reilly</surname><given-names>CA</given-names></name></person-group><article-title>Mechanisms and consequences of variable TRPA1 expression by airway epithelial cells: Effects of TRPV1 genotype and environmental agonists on cellular responses to pollutants in vitro and asthma</article-title><source>Environ Health Perspect</source><volume>131</volume><issue>27009</issue><year>2023</year><pub-id pub-id-type="pmid">36847817</pub-id><pub-id pub-id-type="doi">10.1289/EHP11076</pub-id></element-citation></ref>
<ref id="b18-WASJ-7-5-00369"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>AB</given-names></name><name><surname>Venook</surname><given-names>AP</given-names></name><name><surname>Adam</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Ciombor</surname><given-names>KK</given-names></name><name><surname>Cohen</surname><given-names>SA</given-names></name><name><surname>Cooper</surname><given-names>HS</given-names></name><name><surname>Deming</surname><given-names>D</given-names></name><name><surname>Garrido-Laguna</surname><given-names>I</given-names></name><etal/></person-group><article-title>Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology</article-title><source>J Natl Compr Canc Netw</source><volume>22</volume><issue>e240029</issue><year>2024</year><pub-id pub-id-type="pmid">38862008</pub-id><pub-id pub-id-type="doi">10.6004/jnccn.2024.0029</pub-id></element-citation></ref>
<ref id="b19-WASJ-7-5-00369"><label>19</label><element-citation publication-type="journal"><comment>National Cancer Institute (NCI): Common Terminology Criteria for Adverse Events (CTCAE), 2025. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm&#x0023;ctc_60">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm&#x0023;ctc_60</ext-link>.</comment></element-citation></ref>
<ref id="b20-WASJ-7-5-00369"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ijam</surname><given-names>AH</given-names></name><name><surname>Mshimesh</surname><given-names>BAR</given-names></name><name><surname>Abdulamir</surname><given-names>AS</given-names></name><name><surname>Alsaad</surname><given-names>SF</given-names></name></person-group><article-title>Analysis of cytochrome P450 2C9 gene polymorphism in a sample of iraqi hypertensive patients</article-title><source>Med J Babylon</source><volume>21</volume><fpage>653</fpage><lpage>658</lpage><year>2024</year></element-citation></ref>
<ref id="b21-WASJ-7-5-00369"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowell</surname><given-names>IG</given-names></name><name><surname>Dixon</surname><given-names>KH</given-names></name><name><surname>Pemble</surname><given-names>SE</given-names></name><name><surname>Ketterer</surname><given-names>B</given-names></name><name><surname>Taylor</surname><given-names>JB</given-names></name></person-group><article-title>The structure of the human glutathione S-transferase pi gene</article-title><source>Biochem J</source><volume>255</volume><fpage>79</fpage><lpage>83</lpage><year>1988</year><pub-id pub-id-type="pmid">3196325</pub-id><pub-id pub-id-type="doi">10.1042/bj2550079</pub-id></element-citation></ref>
<ref id="b22-WASJ-7-5-00369"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malempati</surname><given-names>S</given-names></name><name><surname>Agrawal</surname><given-names>N</given-names></name><name><surname>Ravisankar</surname><given-names>D</given-names></name><name><surname>Kothapalli</surname><given-names>VSRT</given-names></name><name><surname>Cheemanapalli</surname><given-names>S</given-names></name><name><surname>Tamanam</surname><given-names>RR</given-names></name><name><surname>Govatati</surname><given-names>S</given-names></name><name><surname>Rao</surname><given-names>PS</given-names></name></person-group><article-title>Role of GSTP1 functional polymorphisms in molecular pathogenesis of colorectal cancer</article-title><source>Hum Gene</source><volume>42</volume><issue>201335</issue><year>2024</year></element-citation></ref>
<ref id="b23-WASJ-7-5-00369"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marensi</surname><given-names>V</given-names></name><name><surname>Yap</surname><given-names>MC</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Berthiaume</surname><given-names>LG</given-names></name><name><surname>Leslie</surname><given-names>EM</given-names></name></person-group><article-title>Glutathione transferase P1 is modified by palmitate</article-title><source>PLoS One</source><volume>19</volume><issue>e0308500</issue><year>2024</year><pub-id pub-id-type="pmid">39269939</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0308500</pub-id></element-citation></ref>
<ref id="b24-WASJ-7-5-00369"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Kridis</surname><given-names>W</given-names></name><name><surname>Toumi</surname><given-names>N</given-names></name><name><surname>Khanfir</surname><given-names>A</given-names></name></person-group><article-title>Chemotherapy-induced peripheral neurotoxicity: Single-centre prospective study</article-title><source>BMJ Support Palliat Care</source><volume>13</volume><fpage>e881</fpage><lpage>e884</lpage><year>2024</year><pub-id pub-id-type="pmid">37142330</pub-id><pub-id pub-id-type="doi">10.1136/spcare-2023-004332</pub-id></element-citation></ref>
<ref id="b25-WASJ-7-5-00369"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Tzeng</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>PM</given-names></name><name><surname>Lin</surname><given-names>JK</given-names></name><name><surname>Lin</surname><given-names>TC</given-names></name><name><surname>Chen</surname><given-names>WS</given-names></name><name><surname>Jiang</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>HS</given-names></name><name><surname>Wang</surname><given-names>WS</given-names></name></person-group><article-title>Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma</article-title><source>Cancer Sci</source><volume>101</volume><fpage>530</fpage><lpage>535</lpage><year>2010</year><pub-id pub-id-type="pmid">19922504</pub-id><pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01418.x</pub-id></element-citation></ref>
<ref id="b26-WASJ-7-5-00369"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inada</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>M</given-names></name><name><surname>Morita</surname><given-names>S</given-names></name><name><surname>Kitagawa</surname><given-names>K</given-names></name><name><surname>Kawada</surname><given-names>K</given-names></name><name><surname>Mitsuma</surname><given-names>A</given-names></name><name><surname>Sawaki</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name></person-group><article-title>Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes</article-title><source>Int J Clin Pharmacol Ther</source><volume>48</volume><fpage>729</fpage><lpage>734</lpage><year>2010</year><pub-id pub-id-type="pmid">20979931</pub-id><pub-id pub-id-type="doi">10.5414/cpp48729</pub-id></element-citation></ref>
<ref id="b27-WASJ-7-5-00369"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname><given-names>M</given-names></name><name><surname>Yoshioka</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Nagayama</surname><given-names>S</given-names></name><name><surname>Matsumoto</surname><given-names>S</given-names></name><name><surname>Nishimura</surname><given-names>T</given-names></name><name><surname>Niimi</surname><given-names>M</given-names></name><name><surname>Teramukai</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>R</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy</article-title><source>Cancer Epidemiol</source><volume>34</volume><fpage>189</fpage><lpage>193</lpage><year>2010</year><pub-id pub-id-type="pmid">20308030</pub-id><pub-id pub-id-type="doi">10.1016/j.canep.2010.02.008</pub-id></element-citation></ref>
<ref id="b28-WASJ-7-5-00369"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecomte</surname><given-names>T</given-names></name><name><surname>Landi</surname><given-names>B</given-names></name><name><surname>Beaune</surname><given-names>P</given-names></name><name><surname>Laurent-Puig</surname><given-names>P</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name></person-group><article-title>Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy</article-title><source>Clin Cancer Res</source><volume>12</volume><fpage>3050</fpage><lpage>3056</lpage><year>2006</year><pub-id pub-id-type="pmid">16707601</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2076</pub-id></element-citation></ref>
<ref id="b29-WASJ-7-5-00369"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>N</given-names></name><name><surname>Okuda</surname><given-names>R</given-names></name><name><surname>Kinoshita</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>H</given-names></name></person-group><article-title>Decomposition kinetics of cisplatin in human biological fluids</article-title><source>J Pharm Pharmacol</source><volume>48</volume><fpage>918</fpage><lpage>924</lpage><year>1996</year><pub-id pub-id-type="pmid">8910854</pub-id><pub-id pub-id-type="doi">10.1111/j.2042-7158.1996.tb06002.x</pub-id></element-citation></ref>
<ref id="b30-WASJ-7-5-00369"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asakura</surname><given-names>T</given-names></name><name><surname>Sasagawa</surname><given-names>A</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Shibata</surname><given-names>SI</given-names></name><name><surname>Marushima</surname><given-names>H</given-names></name><name><surname>Mamori</surname><given-names>S</given-names></name><name><surname>Ohkawa</surname><given-names>K</given-names></name></person-group><article-title>Conformational change in the active center region of GST P1-1, due to binding of a synthetic conjugate of DXR with GSH, enhanced JNK-mediated apoptosis</article-title><source>Apoptosis</source><volume>12</volume><fpage>1269</fpage><lpage>1280</lpage><year>2007</year><pub-id pub-id-type="pmid">17431793</pub-id><pub-id pub-id-type="doi">10.1007/s10495-007-0053-0</pub-id></element-citation></ref>
<ref id="b31-WASJ-7-5-00369"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Win</surname><given-names>S</given-names></name><name><surname>Than</surname><given-names>TA</given-names></name><name><surname>Kaplowitz</surname><given-names>N</given-names></name></person-group><article-title>Mitochondrial P-JNK target, SAB (SH3BP5), in regulation of cell death</article-title><source>Front Cell Dev Biol</source><volume>12</volume><issue>1359152</issue><year>2024</year><pub-id pub-id-type="pmid">38559813</pub-id><pub-id pub-id-type="doi">10.3389/fcell.2024.1359152</pub-id></element-citation></ref>
<ref id="b32-WASJ-7-5-00369"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirmanova</surname><given-names>MV</given-names></name><name><surname>Gavrina</surname><given-names>AI</given-names></name><name><surname>Kovaleva</surname><given-names>TF</given-names></name><name><surname>Dudenkova</surname><given-names>VV</given-names></name><name><surname>Zelenova</surname><given-names>EE</given-names></name><name><surname>Shcheslavskiy</surname><given-names>VI</given-names></name><name><surname>Mozherov</surname><given-names>AM</given-names></name><name><surname>Snopova</surname><given-names>LB</given-names></name><name><surname>Lukyanov</surname><given-names>KA</given-names></name><name><surname>Zagaynova</surname><given-names>EV</given-names></name></person-group><article-title>Insight into redox regulation of apoptosis in cancer cells with multiparametric live-cell microscopy</article-title><source>Sci Rep</source><volume>12</volume><issue>4476</issue><year>2022</year><pub-id pub-id-type="pmid">35296739</pub-id><pub-id pub-id-type="doi">10.1038/s41598-022-08509-1</pub-id></element-citation></ref>
<ref id="b33-WASJ-7-5-00369"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imbaby</surname><given-names>S</given-names></name><name><surname>Elkholy</surname><given-names>SE</given-names></name><name><surname>Faisal</surname><given-names>S</given-names></name><name><surname>Abdelmaogood</surname><given-names>AKK</given-names></name><name><surname>Mehana</surname><given-names>AE</given-names></name><name><surname>Mansour</surname><given-names>BSA</given-names></name><name><surname>Abd El-Moneam</surname><given-names>SM</given-names></name><name><surname>Elaidy</surname><given-names>SM</given-names></name></person-group><article-title>The GSTP1/MAPKs/BIM/SMAC modulatory actions of nitazoxanide: Bioinformatics and experimental evidence in subcutaneous solid Ehrlich carcinoma-inoculated mice</article-title><source>Life Sci</source><volume>319</volume><issue>121496</issue><year>2023</year><pub-id pub-id-type="pmid">36822315</pub-id><pub-id pub-id-type="doi">10.1016/j.lfs.2023.121496</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-WASJ-7-5-00369" position="float">
<label>Figure 1</label>
<caption><p>Chromatogram of the single nucleotide polymorphism, rs1695, on the forward strand. The bases in the frames indicate the polymorphism sites. The letter M in the upper section represents the heterozygous genotype (AG).</p></caption>
<graphic xlink:href="wasj-07-05-00369-g00.tif"/>
</fig>
<fig id="f2-WASJ-7-5-00369" position="float">
<label>Figure 2</label>
<caption><p>Chromatogram of the single nucleotide polymorphism, rs1695, forward strand. The bases in the frames represent the polymorphism sites. The G letter in the upper part represents the homozygous genotype (GG).</p></caption>
<graphic xlink:href="wasj-07-05-00369-g01.tif"/>
</fig>
<fig id="f3-WASJ-7-5-00369" position="float">
<label>Figure 3</label>
<caption><p>Chromatogram of the single nucleotide polymorphism, rs1138272, forward strand. The bases in the frames represent the polymorphism sites. The X letter in the upper part represents the heterozygous genotype (CT).</p></caption>
<graphic xlink:href="wasj-07-05-00369-g02.tif"/>
</fig>
<fig id="f4-WASJ-7-5-00369" position="float">
<label>Figure 4</label>
<caption><p>Chromatogram of the single nucleotide polymorphism, rs1138272, forward strand. The bases in the frames represent the polymorphism sites. The T letter in the upper part represents the homozygous genotype (TT).</p></caption>
<graphic xlink:href="wasj-07-05-00369-g03.tif"/>
</fig>
<table-wrap id="tI-WASJ-7-5-00369" position="float">
<label>Table I</label>
<caption><p>Association of the demographic data of the patients with cumulative neurotoxicity.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Variables</th>
<th align="center" valign="middle">Without CN (n=67)</th>
<th align="center" valign="middle">With CN (n=53)</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Age, years</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Mean &#x00B1; SD</td>
<td align="center" valign="middle">54.16&#x00B1;12.11</td>
<td align="center" valign="middle">50.49&#x00B1;11.96</td>
<td align="center" valign="middle">0.1<sup><xref rid="tfna-WASJ-7-5-00369" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Range</td>
<td align="center" valign="middle">24.40-76.70</td>
<td align="center" valign="middle">18.90-69.50</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Sex</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Male</td>
<td align="center" valign="middle">35</td>
<td align="center" valign="middle">26</td>
<td align="center" valign="middle">0.729<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Female</td>
<td align="center" valign="middle">32</td>
<td align="center" valign="middle">27</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Body mass index, kg/m<sup>2</sup></td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Mean &#x00B1; SD</td>
<td align="center" valign="middle">28.09&#x00B1;6.81</td>
<td align="center" valign="middle">28.16&#x00B1;5.90</td>
<td align="center" valign="middle">0.951<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Range</td>
<td align="center" valign="middle">15.40-49.61</td>
<td align="center" valign="middle">17.57-43.66</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Educational level</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Primary</td>
<td align="center" valign="middle">29 (43.3&#x0025;)</td>
<td align="center" valign="middle">46 (86.8&#x0025;)</td>
<td align="center" valign="middle">0.220<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Secondary</td>
<td align="center" valign="middle">11 (16.4&#x0025;)</td>
<td align="center" valign="middle">12 (22.6&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Higher</td>
<td align="center" valign="middle">13 (19.4&#x0025;)</td>
<td align="center" valign="middle">9 (17.0&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Residence</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Baghdad</td>
<td align="center" valign="middle">42 (62.7&#x0025;)</td>
<td align="center" valign="middle">35 (66.0&#x0025;)</td>
<td align="center" valign="middle">0.492<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;North governorates</td>
<td align="center" valign="middle">8 (11.9&#x0025;)</td>
<td align="center" valign="middle">3 (5.7&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;South governorates</td>
<td align="center" valign="middle">17 (25.4&#x0025;)</td>
<td align="center" valign="middle">15 (28.30&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Family history</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;No</td>
<td align="center" valign="middle">53 (79.1&#x0025;)</td>
<td align="center" valign="middle">44 (83.0&#x0025;)</td>
<td align="center" valign="middle">0.589<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="middle">14 (20.9&#x0025;)</td>
<td align="center" valign="middle">9 (17.0&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Smoking status</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Never</td>
<td align="center" valign="middle">56 (83.6&#x0025;)</td>
<td align="center" valign="middle">38 (71.7&#x0025;)</td>
<td align="center" valign="middle">0.117<sup><xref rid="tfnb-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Ex/current</td>
<td align="center" valign="middle">11 (16.4&#x0025;)</td>
<td align="center" valign="middle">15 (28.3&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">ECOG</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;0</td>
<td align="center" valign="middle">54 (80.6&#x0025;)</td>
<td align="center" valign="middle">41 (77.4&#x0025;)</td>
<td align="center" valign="middle">0.64<sup><xref rid="tfnc-WASJ-7-5-00369" ref-type="table-fn">c</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;1</td>
<td align="center" valign="middle">13 (19.4&#x0025;)</td>
<td align="center" valign="middle">11 (20.8&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;2</td>
<td align="center" valign="middle">0 (0.00&#x0025;)</td>
<td align="center" valign="middle">1 (1.9&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Data were analyzed using the</p></fn>
<fn id="tfna-WASJ-7-5-00369"><p><sup>a</sup>t-test,</p></fn>
<fn id="tfnb-WASJ-7-5-00369"><p><sup>b</sup>Chi-squared test and</p></fn>
<fn id="tfnc-WASJ-7-5-00369"><p><sup>c</sup>Fisher&#x0027;s exact test. CN, cumulative neurotoxicity; ECOG, Eastern Cooperative Oncology Group.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-WASJ-7-5-00369" position="float">
<label>Table II</label>
<caption><p>Disease data associated with oxaliplatin-induced cumulative neurotoxicity.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Variables</th>
<th align="center" valign="middle">Without CN (n=67)</th>
<th align="center" valign="middle">With CN (n=53)</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Past medical history</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;None</td>
<td align="center" valign="middle">39 (58.2&#x0025;)</td>
<td align="center" valign="middle">40 (75.5&#x0025;)</td>
<td align="center" valign="middle">0.0758<sup><xref rid="tfn1-a-WASJ-7-5-00369" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;HT</td>
<td align="center" valign="middle">16 (23.9&#x0025;)</td>
<td align="center" valign="middle">6 (11.3&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;DM</td>
<td align="center" valign="middle">5 (7.5&#x0025;)</td>
<td align="center" valign="middle">5 (9.4&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;HT + DM</td>
<td align="center" valign="middle">5 (7.5&#x0025;)</td>
<td align="center" valign="middle">0 (0.00&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Hypothyroidism</td>
<td align="center" valign="middle">2 (3.0&#x0025;)</td>
<td align="center" valign="middle">2 (3.8&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Primary tumor site</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Colon</td>
<td align="center" valign="middle">37 (55.2&#x0025;)</td>
<td align="center" valign="middle">25 (47.2&#x0025;)</td>
<td align="center" valign="middle">0.602<sup><xref rid="tfn1-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Recto-sigmoid</td>
<td align="center" valign="middle">12 (17.9&#x0025;)</td>
<td align="center" valign="middle">13 (24.5&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Rectum</td>
<td align="center" valign="middle">18 (26.9&#x0025;)</td>
<td align="center" valign="middle">15 (28.3&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Organ metastasis</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;No metastasis</td>
<td align="center" valign="middle">29 (43.3&#x0025;)</td>
<td align="center" valign="middle">22 (37.29&#x0025;)</td>
<td align="center" valign="middle">0.685<sup><xref rid="tfn1-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Liver metastasis</td>
<td align="center" valign="middle">32 (47.8&#x0025;)</td>
<td align="center" valign="middle">23 (43.4&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Other metastasis</td>
<td align="center" valign="middle">7 (10.4&#x0025;)</td>
<td align="center" valign="middle">8 (15.1&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Tumor stage</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;II</td>
<td align="center" valign="middle">3 (4.5&#x0025;)</td>
<td align="center" valign="middle">4 (7.5&#x0025;)</td>
<td align="center" valign="middle">0.752<sup><xref rid="tfn1-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;III</td>
<td align="center" valign="middle">25 (37.3&#x0025;)</td>
<td align="center" valign="middle">18 (34.0&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;IV</td>
<td align="center" valign="middle">39 (58.2&#x0025;)</td>
<td align="center" valign="middle">31 (58.5&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">CEA</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Median</td>
<td align="center" valign="middle">6.0</td>
<td align="center" valign="middle">17.3</td>
<td align="center" valign="middle">0.713<sup><xref rid="tfn1-c-WASJ-7-5-00369" ref-type="table-fn">c</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Range</td>
<td align="center" valign="middle">0.00-2000</td>
<td align="center" valign="middle">0.20-1900</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Data were analyzed using</p></fn>
<fn id="tfn1-a-WASJ-7-5-00369"><p><sup>a</sup>Fisher&#x0027;s exact test,</p></fn>
<fn id="tfn1-b-WASJ-7-5-00369"><p><sup>b</sup>Chi-squared test, or</p></fn>
<fn id="tfn1-c-WASJ-7-5-00369"><p><sup>c</sup>Mann-Whitney U test. CN, cumulative neurotoxicity; HT, hypertension; DM, diabetes mellites; CEA, carcinoembryonic antigen.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIII-WASJ-7-5-00369" position="float">
<label>Table III</label>
<caption><p>Association between the treatment data of patients and oxaliplatin-induced CN.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Variables</th>
<th align="center" valign="middle">Without CN (n=67)</th>
<th align="center" valign="middle">With CN (n=53)</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Standard dose of OHP (mg/m<sup>2</sup>)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;85</td>
<td align="center" valign="middle">27 (40.3&#x0025;)</td>
<td align="center" valign="middle">17 (32.1&#x0025;)</td>
<td align="center" valign="middle">0.353<sup><xref rid="tfn2-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;130</td>
<td align="center" valign="middle">40 (59.7&#x0025;)</td>
<td align="center" valign="middle">36 (67.9&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Given dose of OHP, mg/m<sup>2</sup></td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Mean &#x00B1; SD</td>
<td align="center" valign="middle">178.70&#x00B1;45.56</td>
<td align="center" valign="middle">191.09&#x00B1;45.95</td>
<td align="center" valign="middle">0.143<sup><xref rid="tfn2-c-WASJ-7-5-00369" ref-type="table-fn">c</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Range</td>
<td align="center" valign="middle">100-260</td>
<td align="center" valign="middle">100-270</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Cumulative dose of OHP (mg)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Median</td>
<td align="center" valign="middle">2,100</td>
<td align="center" valign="middle">2,410</td>
<td align="center" valign="middle">0.116<sup><xref rid="tfn2-d-WASJ-7-5-00369" ref-type="table-fn">d</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Range</td>
<td align="center" valign="middle">1,080-3,120</td>
<td align="center" valign="middle">750-3,360</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Concomitant medications n (&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;No</td>
<td align="center" valign="middle">28 (41.8&#x0025;)</td>
<td align="center" valign="middle">31 (58.5&#x0025;)</td>
<td align="center" valign="middle">0.0884<sup><xref rid="tfn2-a-WASJ-7-5-00369" ref-type="table-fn">a</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Statin + RAS-I</td>
<td align="center" valign="middle">18 (26.9&#x0025;)</td>
<td align="center" valign="middle">7 (13.2&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Statin + metformin</td>
<td align="center" valign="middle">6 (9.0&#x0025;)</td>
<td align="center" valign="middle">3 (5.7&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Statin + metformin + RAS-I</td>
<td align="center" valign="middle">4 (6.0&#x0025;)</td>
<td align="center" valign="middle">0 (0.00&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Pregabalin</td>
<td align="center" valign="middle">10 (14.9&#x0025;)</td>
<td align="center" valign="middle">9 (17.0&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Thyroxin</td>
<td align="center" valign="middle">1 (1.5&#x0025;)</td>
<td align="center" valign="middle">3 (5.7&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Chemotherapy settings</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Neoadjuvant</td>
<td align="center" valign="middle">24 (35.8&#x0025;)</td>
<td align="center" valign="middle">19 (35.8&#x0025;)</td>
<td align="center" valign="middle">0.384<sup><xref rid="tfn2-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Palliative</td>
<td align="center" valign="middle">38 (56.7&#x0025;)</td>
<td align="center" valign="middle">28 (52.8&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Adjuvant</td>
<td align="center" valign="middle">5 (7.5&#x0025;)</td>
<td align="center" valign="middle">8 (15.1&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Company</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;X</td>
<td align="center" valign="middle">26 (38.8&#x0025;)</td>
<td align="center" valign="middle">21 (39.6&#x0025;)</td>
<td align="center" valign="middle">0.927<sup><xref rid="tfn2-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Y</td>
<td align="center" valign="middle">41 (61.2&#x0025;)</td>
<td align="center" valign="middle">32 (60.4&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Protocol</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;XELOX</td>
<td align="center" valign="middle">25 (37.3&#x0025;)</td>
<td align="center" valign="middle">21 (39.6&#x0025;)</td>
<td align="center" valign="middle">0.102<sup><xref rid="tfn2-b-WASJ-7-5-00369" ref-type="table-fn">b</xref></sup></td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;XELOX + bevacizumab</td>
<td align="center" valign="middle">18 (26.9&#x0025;)</td>
<td align="center" valign="middle">16 (30.2&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;FOLFOX</td>
<td align="center" valign="middle">12 (17.9&#x0025;)</td>
<td align="center" valign="middle">2 (3.8&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;FOLFOX + bevacizumab</td>
<td align="center" valign="middle">12 (17.9&#x0025;)</td>
<td align="center" valign="middle">14 (26.4&#x0025;)</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Data were analyzed using</p></fn>
<fn id="tfn2-a-WASJ-7-5-00369"><p><sup>a</sup>Fisher&#x0027;s exact test,</p></fn>
<fn id="tfn2-c-WASJ-7-5-00369"><p><sup>c</sup>the t-test,</p></fn>
<fn id="tfn2-b-WASJ-7-5-00369"><p><sup>b</sup>Chi-squared test or</p></fn>
<fn id="tfn2-d-WASJ-7-5-00369"><p><sup>d</sup>Mann-Whitney U test. CN, cumulative neurotoxicity, OHP: Oxaliplatin, RAS-I, renin-angiotensin system inhibitors, FOLFOX, 5-fluorouracil, oxaliplatin (85 mg/m<sup>2</sup>) and leucovorin; XELOX, capecitabine plus oxaliplatin (130 mg/m<sup>2</sup>).</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIV-WASJ-7-5-00369" position="float">
<label>Table IV</label>
<caption><p>Hardy-Weinberg equilibrium test results for <italic>GSTP1</italic> polymorphisms.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">SNP ID</th>
<th align="center" valign="middle">Chi-square (&#x03C7;&#x00B2;)</th>
<th align="center" valign="middle">df</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">HWE Status</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">rs1695</td>
<td align="center" valign="middle">1.77</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">0.412</td>
<td align="center" valign="middle">In equilibrium (NS)</td>
</tr>
<tr>
<td align="left" valign="middle">rs1138272</td>
<td align="center" valign="middle">0.002</td>
<td align="center" valign="middle">1</td>
<td align="center" valign="middle">0.999</td>
<td align="center" valign="middle">In equilibrium (NS)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>Both SNPs were in equilibrium with no significant deviation (P&#x003E;0.05). HWE, Hardy-Weinberg-Equilibrium, df: degree of freedom; SNP, single nucleotide polymorphism.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tV-WASJ-7-5-00369" position="float">
<label>Table V</label>
<caption><p>rs1695 polymorphism as a risk factor for oxaliplatin-induced CN (genotype and allele analysis).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">rs1695</th>
<th align="center" valign="middle">Without CN (n=67) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=53) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">44 (65.67)</td>
<td align="center" valign="middle">22 (41.51)</td>
<td align="center" valign="middle">0.026</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG</td>
<td align="center" valign="middle">19 (28.36)</td>
<td align="center" valign="middle">23 (43.4)</td>
<td align="center" valign="middle">0.029</td>
<td align="center" valign="middle">2.42 (1.09-5.36)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">4 (5.97)</td>
<td align="center" valign="middle">8 (15.09)</td>
<td align="center" valign="middle">0.037</td>
<td align="center" valign="middle">4.0 (1.08-14.74)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA + AG</td>
<td align="center" valign="middle">63 (94.03)</td>
<td align="center" valign="middle">45 (84.91)</td>
<td align="center" valign="middle">0.109</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">4 (5.97)</td>
<td align="center" valign="middle">8 (15.09)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.8(0.79-9.87)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">44 (65.67)</td>
<td align="center" valign="middle">22 (41.51)</td>
<td align="center" valign="middle">0.009</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG + GG</td>
<td align="center" valign="middle">23 (34.33)</td>
<td align="center" valign="middle">31 (58.49)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.88 (1.36-6.08)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;A</td>
<td align="center" valign="middle">107 (79.85)</td>
<td align="center" valign="middle">67 (63.21)</td>
<td align="center" valign="middle">0.005</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;G</td>
<td align="center" valign="middle">27 (20.15)</td>
<td align="center" valign="middle">39 (36.79)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.31 (1.29-4.11)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tVI-WASJ-7-5-00369" position="float">
<label>Table VI</label>
<caption><p>rs1138272 polymorphism as a risk factor for oxaliplatin-induced CN (genotype and allele analysis).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">rs1138272</th>
<th align="center" valign="middle">Without CN (n=67) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=53) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">59 (88.06)</td>
<td align="center" valign="middle">32 (60.78)</td>
<td align="center" valign="middle">0.003</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT</td>
<td align="center" valign="middle">7 (10.45)</td>
<td align="center" valign="middle">20 (37.74)</td>
<td align="center" valign="middle">0.001</td>
<td align="center" valign="middle">5.27 (2.0-13.79)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1 (1.49)</td>
<td align="center" valign="middle">1 (1.89)</td>
<td align="center" valign="middle">0.669</td>
<td align="center" valign="middle">1.84 (0.11-30.47)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC+CT</td>
<td align="center" valign="middle">66 (98.51)</td>
<td align="center" valign="middle">52 (98.11)</td>
<td align="center" valign="middle">0.867</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1 (1.49)</td>
<td align="center" valign="middle">1 (1.89)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">1.27 (0.08-20.78)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">59 (88.06)</td>
<td align="center" valign="middle">32 (60.78)</td>
<td align="center" valign="middle">0.001</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT + TT</td>
<td align="center" valign="middle">8 (11.49)</td>
<td align="center" valign="middle">21 (39.62)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">4.84 (1.93-12.16)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;C</td>
<td align="center" valign="middle">125 (93.28)</td>
<td align="center" valign="middle">84 (79.25)</td>
<td align="center" valign="middle">0.002</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;T</td>
<td align="center" valign="middle">9 (6.72)</td>
<td align="center" valign="middle">22 (20.75)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">3.64 (1.6-8.29)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tVII-WASJ-7-5-00369" position="float">
<label>Table VII</label>
<caption><p>Association between the rs1695 polymorphism and oxaliplatin-induced CN at doses &#x003C;1,000 mg/m<sup>2</sup>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Rs1695</th>
<th align="center" valign="middle">Without CN (n=100) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=20) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">58(58)</td>
<td align="center" valign="middle">8(40)</td>
<td align="center" valign="middle">0.043</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG</td>
<td align="center" valign="middle">35(35)</td>
<td align="center" valign="middle">7(35)</td>
<td align="center" valign="middle">0.721</td>
<td align="center" valign="middle">1.15 (0.52-2.53)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">7(7)</td>
<td align="center" valign="middle">5(25)</td>
<td align="center" valign="middle">0.012</td>
<td align="center" valign="middle">7.7 (1.56-37.96)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA + AG</td>
<td align="center" valign="middle">93(93)</td>
<td align="center" valign="middle">15(75)</td>
<td align="center" valign="middle">0.022</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">7(7)</td>
<td align="center" valign="middle">5(25)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">4.43 (1.24-15.78)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">58(58)</td>
<td align="center" valign="middle">8(40)</td>
<td align="center" valign="middle">0.145</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG + GG</td>
<td align="center" valign="middle">42(42)</td>
<td align="center" valign="middle">12(60)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.07 (0.78-5.51)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;A</td>
<td align="center" valign="middle">151 (75.5)</td>
<td align="center" valign="middle">23 (57.5)</td>
<td align="center" valign="middle">0.022</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;G</td>
<td align="center" valign="middle">49 (24.5)</td>
<td align="center" valign="middle">17 (42.5)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.29 (1.27-4.61</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tVIII-WASJ-7-5-00369" position="float">
<label>Table VIII</label>
<caption><p>Association between the rs1695 polymorphism and oxaliplatin-induced CN at doses &#x003E;1,000 mg/m<sup>2</sup>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">rs1695</th>
<th align="center" valign="middle">Without CN (n=87) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=33) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">58 (66.67)</td>
<td align="center" valign="middle">8 (24.24)</td>
<td align="center" valign="middle">0.001</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG</td>
<td align="center" valign="middle">20 (22.99)</td>
<td align="center" valign="middle">22 (66.67)</td>
<td align="center" valign="middle">&#x003C;0.001</td>
<td align="center" valign="middle">5.5 (2.26-13.34)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">9 (10.34)</td>
<td align="center" valign="middle">3 (9.09)</td>
<td align="center" valign="middle">0.492</td>
<td align="center" valign="middle">1.67 (0.39-7.16)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA + AG</td>
<td align="center" valign="middle">78 (89.66)</td>
<td align="center" valign="middle">30 (90.91)</td>
<td align="center" valign="middle">0.691</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;GG</td>
<td align="center" valign="middle">9 (10.71)</td>
<td align="center" valign="middle">3 (8.33)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.76 (0.19-2.98)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AA</td>
<td align="center" valign="middle">58 (66.67)</td>
<td align="center" valign="middle">8 (24.24)</td>
<td align="center" valign="middle">0.001</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;AG + GG</td>
<td align="center" valign="middle">29 (34.52)</td>
<td align="center" valign="middle">25 (69.44)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">4.31 (1.86-9.98)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;A</td>
<td align="center" valign="middle">136 (78.16)</td>
<td align="center" valign="middle">38 (57.58)</td>
<td align="center" valign="middle">0.011</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;G</td>
<td align="center" valign="middle">38 (21.84)</td>
<td align="center" valign="middle">28 (42.42)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.18 (1.2-3.95)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIX-WASJ-7-5-00369" position="float">
<label>Table IX</label>
<caption><p>Association between the rs1138272 polymorphism with oxaliplatin-induced cumulative neurotoxicity at doses &#x003C;1,000 mg/m<sup>2</sup>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">rs1138272</th>
<th align="center" valign="middle">Without CN (n=100) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=20) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025;CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">81(81)</td>
<td align="center" valign="middle">10(50)</td>
<td align="center" valign="middle">0.017</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT</td>
<td align="center" valign="middle">18(18)</td>
<td align="center" valign="middle">9(45)</td>
<td align="center" valign="middle">0.004</td>
<td align="center" valign="middle">4.05 (1.44-11.4)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1(1)</td>
<td align="center" valign="middle">1(5)</td>
<td align="center" valign="middle">0.150</td>
<td align="center" valign="middle">8.1 (0.47-139.8)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC + CT</td>
<td align="center" valign="middle">99(9)</td>
<td align="center" valign="middle">19(19)</td>
<td align="center" valign="middle">0.250</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1(1)</td>
<td align="center" valign="middle">1(5)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">5.21 (0.31-86.97)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">81(81)</td>
<td align="center" valign="middle">10(50)</td>
<td align="center" valign="middle">0.005</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT + TT</td>
<td align="center" valign="middle">19(95)</td>
<td align="center" valign="middle">10(50)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">4.05 (1.55-11.69)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;C</td>
<td align="center" valign="middle">180(9)</td>
<td align="center" valign="middle">29 (72.5)</td>
<td align="center" valign="middle">0.004</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;T</td>
<td align="center" valign="middle">20 10)</td>
<td align="center" valign="middle">11 (27.5)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">3.41 1.48-7.86)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tX-WASJ-7-5-00369" position="float">
<label>Table X</label>
<caption><p>Association between the rs1138272 polymorphism and oxaliplatin-induced CN at doses &#x003E;1,000 mg/m<sup>2</sup>.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">rs1138272</th>
<th align="center" valign="middle">Without CN (n=84) (&#x0025;)</th>
<th align="center" valign="middle">With CN (n=36) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Codominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">60 (71.43)</td>
<td align="center" valign="middle">31 (86.11)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT</td>
<td align="center" valign="middle">23 (27.38)</td>
<td align="center" valign="middle">4 (11.11)</td>
<td align="center" valign="middle">0.063</td>
<td align="center" valign="middle">0.33 (0.11-1.06)</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1 (1.19)</td>
<td align="center" valign="middle">1 (2.78)</td>
<td align="center" valign="middle">0.645</td>
<td align="center" valign="middle">1.93 (0.12-32.0)</td>
</tr>
<tr>
<td align="left" valign="middle">Dominant model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC + CT</td>
<td align="center" valign="middle">83 (98.81)</td>
<td align="center" valign="middle">35 (97.22)</td>
<td align="center" valign="middle">0.546</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;TT</td>
<td align="center" valign="middle">1 (1.19)</td>
<td align="center" valign="middle">1 (2.78)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.37 (0.14-39.0)</td>
</tr>
<tr>
<td align="left" valign="middle">Recessive model</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CC</td>
<td align="center" valign="middle">60 (71.43)</td>
<td align="center" valign="middle">31 (86.11)</td>
<td align="center" valign="middle">0.092</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;CT + TT</td>
<td align="center" valign="middle">24 (28.57)</td>
<td align="center" valign="middle">5 (13.89)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.40 (0.14-1.16)</td>
</tr>
<tr>
<td align="left" valign="middle">Alleles</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;C</td>
<td align="center" valign="middle">143 (85.12)</td>
<td align="center" valign="middle">66 (91.67)</td>
<td align="center" valign="middle">0.172</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;T</td>
<td align="center" valign="middle">25 (14.88)</td>
<td align="center" valign="middle">6 (8.33)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.52 (0.21-1.33)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tXI-WASJ-7-5-00369" position="float">
<label>Table XI</label>
<caption><p>Dose-independent genetic risk: rs1695 AG/GG genotypes exhibit a progressive association with higher-grade oxaliplatin-induced CN.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" colspan="5">A, Grade 1 CN</th>
</tr>
<tr>
<th align="left" valign="middle">Genotypes/alleles</th>
<th align="center" valign="middle">Without grade 1 CN (n=96)</th>
<th align="center" valign="middle">With grade 1 CN (n=24) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">AA</td>
<td align="center" valign="middle">59 (61.46)</td>
<td align="center" valign="middle">7 (29.17)</td>
<td align="center" valign="middle">0.033</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">AG</td>
<td align="center" valign="middle">28 (29.17)</td>
<td align="center" valign="middle">14 (58.33)</td>
<td align="center" valign="middle">0.010</td>
<td align="center" valign="middle">3.62 (1.36-9.65)</td>
</tr>
<tr>
<td align="left" valign="middle">GG</td>
<td align="center" valign="middle">9 (9.38)</td>
<td align="center" valign="middle">3 (12.50)</td>
<td align="center" valign="middle">0.666</td>
<td align="center" valign="middle">1.45 (0.27-7.84)</td>
</tr>
<tr>
<td align="left" valign="middle">A</td>
<td align="center" valign="middle">146 (76.04)</td>
<td align="center" valign="middle">28 (58.33)</td>
<td align="center" valign="middle">0.015</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">G</td>
<td align="center" valign="middle">46 (23.96)</td>
<td align="center" valign="middle">20 (41.67)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.27 (1.17-4.4)</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">B, Grade 2 CN</td>
</tr>
<tr>
<td align="left" valign="middle">Genotypes/alleles</td>
<td align="center" valign="middle">Without grade 2 CN (n=105) (&#x0025;)</td>
<td align="center" valign="middle">With grade 2 CN (n=15) (&#x0025;)</td>
<td align="center" valign="middle">P-value</td>
<td align="center" valign="middle">OR (95&#x0025; CI)</td>
</tr>
<tr>
<td align="left" valign="middle">AA</td>
<td align="center" valign="middle">60 (57.14)</td>
<td align="center" valign="middle">6(40)</td>
<td align="center" valign="middle">0.091</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">AG</td>
<td align="center" valign="middle">37 (35.24)</td>
<td align="center" valign="middle">5 (33.33)</td>
<td align="center" valign="middle">0.638</td>
<td align="center" valign="middle">1.35 (0.38-3.74)</td>
</tr>
<tr>
<td align="left" valign="middle">GG</td>
<td align="center" valign="middle">8 (7.62)</td>
<td align="center" valign="middle">4 (26.67)</td>
<td align="center" valign="middle">0.031</td>
<td align="center" valign="middle">5.0 (1.56&#x2013;21.63)</td>
</tr>
<tr>
<td align="left" valign="middle">A</td>
<td align="center" valign="middle">157 (74.76)</td>
<td align="center" valign="middle">17 (56.67)</td>
<td align="center" valign="middle">0.042</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">G</td>
<td align="center" valign="middle">53 (25.24)</td>
<td align="center" valign="middle">13 (43.33)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.65 1.03-5.0)</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">C, Grade 3 CN</td>
</tr>
<tr>
<td align="left" valign="middle">Genotypes/alleles</td>
<td align="center" valign="middle">Without grade 3 CN (n=106) (&#x0025;)</td>
<td align="center" valign="middle">With grade 3 CN (n=14) (&#x0025;)</td>
<td align="center" valign="middle">P-value</td>
<td align="center" valign="middle">OR (95&#x0025; CI)</td>
</tr>
<tr>
<td align="left" valign="middle">AA</td>
<td align="center" valign="middle">63 (59.43)</td>
<td align="center" valign="middle">3 (21.43)</td>
<td align="center" valign="middle">0.042</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">AG</td>
<td align="center" valign="middle">34 (32.07)</td>
<td align="center" valign="middle">8 (57.14)</td>
<td align="center" valign="middle">0.024</td>
<td align="center" valign="middle">4.94 (01.23-19.85)</td>
</tr>
<tr>
<td align="left" valign="middle">GG</td>
<td align="center" valign="middle">9 (8.49)</td>
<td align="center" valign="middle">3 (21.43)</td>
<td align="center" valign="middle">0.029</td>
<td align="center" valign="middle">6.2 1.22-40.12)</td>
</tr>
<tr>
<td align="left" valign="middle">A</td>
<td align="center" valign="middle">140 (66.04)</td>
<td align="center" valign="middle">14(50)</td>
<td align="center" valign="middle">0.001</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">G</td>
<td align="center" valign="middle">72 (33.96)</td>
<td align="center" valign="middle">14(50)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">3.65 (1.7-8.01)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tXII-WASJ-7-5-00369" position="float">
<label>Table XII</label>
<caption><p>Dose-independent genetic risk: Association between the rs1138272 polymorphism and oxaliplatin-induced CN.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" colspan="5">A, Grade 1 CN</th>
</tr>
<tr>
<th align="left" valign="middle">Genotypes/alleles</th>
<th align="center" valign="middle">Without grade 1 CN (n=96) (&#x0025;)</th>
<th align="center" valign="middle">With grade 1 CN (n=24) (&#x0025;)</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">OR (95&#x0025; CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">CC</td>
<td align="center" valign="middle">74 (77.08)</td>
<td align="center" valign="middle">17 (70.83)</td>
<td align="center" valign="middle">0.565</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">CT</td>
<td align="center" valign="middle">21 (21.88)</td>
<td align="center" valign="middle">6(25)</td>
<td align="center" valign="middle">0.684</td>
<td align="center" valign="middle">1.24 (0.43-3.55)</td>
</tr>
<tr>
<td align="left" valign="middle">TT</td>
<td align="center" valign="middle">1 (1.04)</td>
<td align="center" valign="middle">1 (4.17)</td>
<td align="center" valign="middle">0.307</td>
<td align="center" valign="middle">4.35 (0.26-73.14)</td>
</tr>
<tr>
<td align="left" valign="middle">C</td>
<td align="center" valign="middle">169 (88.02)</td>
<td align="center" valign="middle">40 (83.33)</td>
<td align="center" valign="middle">0.389</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">T</td>
<td align="center" valign="middle">23 (11.98)</td>
<td align="center" valign="middle">8 (16.67)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">1.47 (0.61-3.53)</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">B, Grade 2 CN</td>
</tr>
<tr>
<td align="left" valign="middle">Genotypes/alleles</td>
<td align="center" valign="middle">Without grade 2 CN (n=105) (&#x0025;)</td>
<td align="center" valign="middle">With grade 2 CN (n=15) (&#x0025;)</td>
<td align="center" valign="middle">P-value</td>
<td align="center" valign="middle">OR (95&#x0025; CI)</td>
</tr>
<tr>
<td align="left" valign="middle">CC</td>
<td align="center" valign="middle">82 (78.10)</td>
<td align="center" valign="middle">9(60)</td>
<td align="center" valign="middle">0.258</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">CT</td>
<td align="center" valign="middle">21(20)</td>
<td align="center" valign="middle">6(40)</td>
<td align="center" valign="middle">0.100</td>
<td align="center" valign="middle">2.60 (0.83-8.13)</td>
</tr>
<tr>
<td align="left" valign="middle">TT</td>
<td align="center" valign="middle">2 (1.90)</td>
<td align="center" valign="middle">0 (0)</td>
<td align="center" valign="middle">0.202</td>
<td align="center" valign="middle">0.41 (0.41-7.23)</td>
</tr>
<tr>
<td align="left" valign="middle">C</td>
<td align="center" valign="middle">185 (88.10)</td>
<td align="center" valign="middle">24(80)</td>
<td align="center" valign="middle">0.090</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">T</td>
<td align="center" valign="middle">25 (13.16)</td>
<td align="center" valign="middle">6(20)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">2.26 (0.88-5.82)</td>
</tr>
<tr>
<td align="left" valign="middle" colspan="5">C, Grade 3 CN</td>
</tr>
<tr>
<td align="left" valign="middle">Genotypes/alleles</td>
<td align="center" valign="middle">Without grade 3 CN (n=106) (&#x0025;)</td>
<td align="center" valign="middle">With grade 3 CN (n=14) (&#x0025;)</td>
<td align="center" valign="middle">P-value</td>
<td align="center" valign="middle">OR (95&#x0025; CI)</td>
</tr>
<tr>
<td align="left" valign="middle">CC</td>
<td align="center" valign="middle">84 (79.25)</td>
<td align="center" valign="middle">7(50)</td>
<td align="center" valign="middle">0.052</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">CT</td>
<td align="center" valign="middle">21 (19.81)</td>
<td align="center" valign="middle">6 (42.86)</td>
<td align="center" valign="middle">0.043</td>
<td align="center" valign="middle">3.43 (1.04-11.28)</td>
</tr>
<tr>
<td align="left" valign="middle">TT</td>
<td align="center" valign="middle">1 (0.94)</td>
<td align="center" valign="middle">1 (7.14)</td>
<td align="center" valign="middle">0.090</td>
<td align="center" valign="middle">3.43 (1.04-11.28)</td>
</tr>
<tr>
<td align="left" valign="middle">C</td>
<td align="center" valign="middle">189 (89.15)</td>
<td align="center" valign="middle">20 (71.23)</td>
<td align="center" valign="middle">0.052</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="middle">T</td>
<td align="center" valign="middle">23 (10.85)</td>
<td align="center" valign="middle">8 (28.57)</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">3.29 (1.3-8.31)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>P-values were calculated using binary logistic regression. CN, cumulative neurotoxicity. The CT genotype emerges as a significant risk factor in grade 3 cases (OR, 3.43).</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
